Tue 01/30/2024 05:30 AM
Share this article:
 
U.K. private equity firm Exponent is closing in on acquiring Irish pharmaceutical company Chanelle Pharma in a deal worth more than €300 million, according to The Times.

Michael Burke, who founded Chanelle Pharma in 1985, mandated Rothschild as the sell-side advisor for the company last year, according to the article.

The company generates a profit of about €25 million and is likely to generate a multiple of 10x to 12x this amount, according to the article.

Companies in the European pharmaceutical sector have on average generated valuations of 10.4x pro forma EBITDA, according to Fundamentals by Reorg.

Based in County Galway, Chanelle Pharma has human and veterinary­ pharmaceutical licenses in Europe, Canada, South Africa, Australia, New Zealand and Japan.

In 2018, the company presented an €85 million investment plan, which sought to double its manufacturing capacity with 96 new products.

Chanelle Pharma holds veterinary licenses for about 3,000 animal medicines, and licenses for about 1,800 human drugs.
Share this article:
This article is an example of the content you may receive if you subscribe to a product of Reorg Research, Inc. or one of its affiliates (collectively, “Reorg”). The information contained herein should not be construed as legal, investment, accounting or other professional services advice on any subject. Reorg, its affiliates, officers, directors, partners and employees expressly disclaim all liability in respect to actions taken or not taken based on any or all the contents of this publication. Copyright © 2024 Reorg Research, Inc. All rights reserved.
Thank you for signing up
for Reorg on the Record!